Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 12318413
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
granted -
US 12319744
Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
granted -
US 12318401
Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy
granted -
US 12319703
Macrocyclic fused pyrazoles as Mcl-1 inhibitors
granted -
US 12319740
Methods for production of tissue resident memory-like T cells and use thereof
granted -
US 12319737
NK engager molecules and methods of use thereof
granted -
US 12319708
Agonists of peroxisome proliferator-activated receptor alpha (PPARΞ±) and methods of use
granted -
US 12318439
Attenuating viral mutations in protein genes
granted -
US 12310996
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
granted -
US 12312616
CRISPR-Cas effector polypeptides and methods of use thereof
granted -
US 12310986
Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress
granted -
US 12312334
Quinoxaline compounds and uses thereof
granted -
US 12313635
Biomarker for thoracic aortic aneurysm
granted -
US 12312589
RNA-nanostructured double robots and methods of use thereof
granted -
US 12311030
Antibody-sting agonist conjugates and their use in immunotherapy
granted -
US 12310934
Methods of treatment of spontaneous preterm birth
granted -
US 12310997
Compositions and methods of treating ocular diseases
granted -
US 12311053
Nanotube-vesicle compositions and uses thereof
granted -
US 12311169
Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
granted -
US 12310954
Salivary gland regeneration
granted -
US 12310988
BCMA chimeric antigen receptors and uses thereof
granted -
US 12303479
Chloride intracellular channel 1 for regulation of food intake
granted -
US 12303602
Compositions, methods and uses for thermally stable multi-targeted antigens
granted -
US 12304930
Prefusion-stabilized hMPV F proteins
granted -
US 12303594
Antimicrobial and anti-inflammatory compositions
granted -
US 12295971
Compositions and methods for enhancing adoptive T cell therapeutics
granted -
US 12296023
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
granted -
US 12295929
Intravenous baclofen formulations and treatment methods
granted -
US 12297241
Method to engineer transplantable human tissues
granted -
US 12297259
Aspergillus antigen chimeric receptors and use thereof
granted -
US 12295974
Compositions and methods for transplantation of colon microbiota
granted -
US 12297447
Gene therapy for juvenile Batten disease
granted -
US 12297452
Methods or generating T-cells from stem cells and immunotherapeutic methods using the T-cells
granted -
US 12296048
Polymer particles for neutrophil injury
granted -
US 12296066
Methods of wound healing with Serp-1 polypeptides
granted -
US 12292445
Methods of selecting subjects for treatment with metabolomic modulators
granted -
US 12290588
Peptide having activity of improving skin condition and use thereof
granted -
US 12291502
Topoisomerase II-alpha inhibitors and methods of treating cancer using the same
granted -
US 12285472
Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
granted -
US 12285490
ASH1L degraders and methods of treatment therewith
granted -
US 12285627
Fabrication and irradiation of a radioactive isotope skin patch
granted -
US 12285404
Prevention of rosacea inflammation
granted -
US 12286407
Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases
granted -
US 12285357
Intraocular drug delivery systems and methods of use
granted -
US 12285496
Gene therapy for haploinsufficiency
granted -
US 12286480
Modulators of ROR1-ROR2 binding
granted -
US 12286406
Inhibitors of receptor interacting protein kinase I for the treatment of disease
granted -
US 12281021
System and method for making boron oxide nanoparticles
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory